| Literature DB >> 34041835 |
Tabara Yasuharu1,2, Kazuya Setoh1, Takahisa Kawaguchi1, Takeo Nakayama2,3, Fumihiko Matsuda1,2.
Abstract
Faster pulse wave velocity (PWV) is known to be associated with the incidence of cardiovascular diseases (CVD). The aim of this study was to clarify the hypothesis that PWV may be associated with future CVD events even when its time-dependent changes were adjusted. We also investigated a prognostic significance of cardio-ankle vascular index, another index of arterial stiffness. Study participants included 8850 community residents. The repeated measures of the clinical parameters at 5.0 years after the baseline were available for 7249 of the participants. PWV was calculated using the arterial waveforms measured at the brachia and ankles (baPWV). The cardio-ankle vascular index was calculated by estimated pulse transit time from aortic valve to tibial artery. During the 8.53 years follow-up period, we observed 215 cases of CVD. The incidence rate increased linearly with baPWV quartiles (per 10 000 person-years: Q1, 2.7; Q2, 12.6; Q3, 22.5; Q4, 76.2), and the highest quartile was identified as an independent determinant of incident CVD by conventional Cox proportional hazard analysis adjusted for known risk factors [hazard ratio (HR), 4.00; p = .007]. Per unit HR of baPWV (HR, 1.15; p < .001) remained significant in the time-dependent Cox regression analysis including baPWV and other clinical values measured at 5-year after the baseline as time-varying variables (HR, 1.14; p < .001). The cardio-ankle vascular index was also associated with CVD with similar manner though the associations were less clear than that of baPWV. baPWV is a good risk marker for the incidence of CVD.Entities:
Keywords: cardio-ankle vascular index; cardiovascular disease; general population; longitudinal study; pulse wave velocity
Mesh:
Year: 2021 PMID: 34041835 PMCID: PMC8678776 DOI: 10.1111/jch.14294
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738
Clinical characteristics of study participants
| Baseline ( | Follow‐up ( | |
|---|---|---|
| Age (years) | 53.9 ± 13.1 | 59.8 ± 12.6 |
| Male sex (%) | 33.5 | 33.5 |
| BMI (kg/m2) | 22.3 ± 3.3 | 22.2 ± 3.3 |
| Smoking habit (current/past/never, %) | 14.7/19.8/65.5 | 10.4/21.0/68.5 |
| Blood pressure | ||
| Systolic (mmHg) | 124 ± 18 | 125 ± 18 |
| Diastolic (mmHg) | 76 ± 11 | 72 ± 11 |
| Heart rate (beats/min) | 69 ± 10 | 68 ± 10 |
| Antihypertensive medication (%) | 16.3 | 25.5 |
| Hypertension (%) | 30.6 | 37.5 |
| Glycemic markers | ||
| Glucose (mg/dl) | 90 ± 15 | 88 ± 15 |
| HbA1c (%) | 5.5 ± 0.5 | 5.6 ± 0.5 |
| Hypoglycemic medication (%) | 2.7 | 5.0 |
| Diabetes (%) | 4.1 | 3.9 |
| Lipid markers | ||
| HDL cholesterol (mg/dl) | 65 ± 17 | 67 ± 17 |
| LDL cholesterol (mg/dl) | 124 ± 31 | 119 ± 29 |
| Lipid‐lowering medication (%) | 11.6 | 21.7 |
| Dyslipidemia (%) | 41.2 | 43.1 |
| Renal function | ||
| Creatinine (mg/dl) | 0.7 ± 0.2 | 0.7 ± 0.2 |
| eGFR (ml/min/1.73 m2) | 79.2 ± 15.6 | 76.5 ± 14.6 |
| Urinary albumin (mg/day) | 19 ± 81 | 18 ± 76 |
| Albuminuria (%) | 8.8 | 8.2 |
| CKD (%) | 16.0 | 17.0 |
| BNP (pg/ml) | 17.0 ± 19.3 | 21.9 ± 22.2 |
| baPWV (cm/s) | 1,265 ± 216 | 1,313 ± 239 |
| CAVI | 7.40 ± 1.09 | 7.91 ± 1.15 |
Values are mean ± standard deviation or frequency. Hypertension was defined as either systolic blood pressure (BP) ≥140 mmHg, diastolic BP ≥90 mmHg or taking antihypertensive drugs. Diabetes was defined as either fasting (≥6 h after last meal) glucose ≥126 mg/dl, nonfasting glucose ≥200 mg/dl, hemoglobin A1c (HbA1c) ≥6.5%, or using hypoglycemic drugs. Dyslipidemia was defined as either high‐density lipoprotein (HDL) cholesterol <40 mg/dl, low‐density lipoprotein (LDL) cholesterol ≥140 mg/dl, or taking lipid‐lowering drugs. Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2, or albuminuria (urinary albumin ≥30 mg/day).
Abbreviations: baPWV, brachial‐ankle pulse wave velocity; BMI, body mass index; BNP, B‐type natriuretic peptide; CAVI, cardio‐ankle vascular index; HbA1c, hemoglobin A1c.
Incidence rate of CVD by the quartiles of baseline baPWV or CAVI
| Baseline baPWV quartiles | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| baPWV (cm/s) | 1,028 ± 54 | 1,163 ± 36 | 1,303 ± 48 | 1,563 ± 152 |
| Number of participants | 2201 | 2217 | 2209 | 2223 |
| Total participants | ||||
| Person‐years | 18 660 | 19 000 | 19 075 | 18 765 |
| Number of CVD | 5 | 24 | 43 | 143 |
| Incidence rate | 2.7 | 12.6 | 22.5 | 76.2 |
| Men | ||||
| Person‐years | 3951 | 6850 | 6903 | 7220 |
| Number of CVD | 2 | 14 | 24 | 88 |
| Incidence rate | 5.1 | 20.4 | 34.8 | 121.9 |
| Women | ||||
| Person‐years | 14 709 | 12 150 | 12 172 | 11 544 |
| Number of CVD | 3 | 10 | 19 | 55 |
| Incidence rate | 2.0 | 8.2 | 15.6 | 47.6 |
Cardiovascular disease (CVD) includes symptomatic stroke, myocardial infarction, or percutaneous coronary intervention. The incidence rate is shown per 10 000 person‐years.
Abbreviations: baPWV, brachial‐ankle pulse wave velocity; CAVI, cardio‐ankle vascular index.
Cox regression analysis for incident CVD
| Cox regression model | Time‐dependent Cox regression model | ||||||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |||||
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| ||
| baPWV | 1st quartile | reference | |||||
| 2nd quartile | 2.02 (0.75 − 5.41) | .162 | |||||
| 3rd quartile | 1.95 (0.73 − 5.25) | .184 | |||||
| 4th quartile | 4.00 (1.46 − 10.98) | .007 | |||||
| Per 1 m/s | 1.15 (1.07 − 1.24) | <.001 | 1.14 (1.06 − 1.23) | <.001 | |||
| CAVI | 1st quartile | reference | |||||
| 2nd quartile | 0.98 (0.46 − 2.12) | .966 | |||||
| 3rd quartile | 0.97 (0.46 − 2.05) | .936 | |||||
| 4th quartile | 1.70 (0.80 − 3.63) | .167 | |||||
| Per 1 unit | 1.26 (1.07 − 1.48) | .006 | 1.23 (1.04 − 1.44) | .013 | |||
Adjusted factors in all Models were age, sex, body mass index, current smoking, mean blood pressure, heart rate, hemoglobin A1c, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, urinary albumin (≥30 mg/day), and B‐type natriuretic peptide (≥100 pg/ml). Overall p values of each model for Schoenfeld residuals test were as follows: baPWV: Model 1, 0.450; Model 2, 0.352; Model 3, 0.169 and CAVI: Model 1, 0.346; Model 2, 0.518; Model 3, 0.240. Full results of the regression analysis are shown in Tables S3 and S4.
Abbreviations: baPWV, brachial‐ankle pulse wave velocity; CAVI, cardio‐ankle vascular index; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.
FIGURE 1Penalized cubic splines of the association between the arterial stiffness parameters and the hazard ratio for CVD events. Solid line, hazard ratio; dashed line, 95% confidence interval. Adjusted factors are age, sex, body mass index, smoking, mean blood pressure, heart rate, hemoglobin A1c, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, urinary albumin (≥30 mg/day), and B‐type natriuretic peptide (≥100 pg/ml). baPWV, brachial‐ankle pulse wave velocity; CAVI, cardio‐ankle vascular index